The novel Hsp90 inhibitor XL888 is undergoing clinical investigation for use in conjunction with the rapidly accelerated fibrosarcoma (RAF) kinase inhibitor vemurafenib to treat unresectable melanoma. The addition of XL888 to current regimens may serve an additional purpose by blocking the RAF inhibitor paradox. Such activity could reduce adverse events in patients and provide a biomarker for the successful inhibition of Hsp90 target proteins.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4568562 | PMC |
| http://dx.doi.org/10.1038/jid.2015.239 | DOI Listing |
Publication Analysis
Top Keywords
raf inhibitor
8
inhibitor paradox
8
broad stroke
4
stroke hsp90
4
hsp90 inhibitors
4
inhibitors painting
4
painting raf
4
inhibitor
4
paradox novel
4
novel hsp90
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!